Covid-19: See latest data on suppliers and inventory

KINETA logo

KINETA

219 Terry Avenue N, Suite 300, Seattle, WA 98109, United States
Kineta, Inc specifies their major offering areas as: Immuno-oncology, Neuroscience, and Biodefense.
DUNS #:
809832558
CAGE Code:
50NT6
Type:
Manufacturer
Employees:
10-50
Annual Revenue:
$5M-$50M
Year Founded:
2008
Country of Origin:
United States
Sectors Served:
US Federal
Company Security Level:
Unknown
Credit Card Usage:
No

Specialties and Expertise:

Immuno-therapy, Virology, Immunology, Neuroscience, Biodefense, Antiviral Therapies, Antigen, Vaccine Development, Anti-viral compounds, COVID-19 Research.

Contact/Location Info3

Size and minority status

Size
Small business
Ownership
African American
Alaska Native
Asian-Indian
Asian-Pacific
Hispanic
Minority-Unspecified
Native American
Native Hawaiian
Tribal
Unspecified
Veteran
Woman
Government Set-Aside Programs
AbilityOne
HUBZone
SBA 8(a)
SDVOSB
Small Disadvantaged Business (SDB)
Woman Owned Small Business (WOSB)

Past experience5

SBIR
Agonists of the RIG-I Innate Immune Pathway
Through Phase I studies, we have identified five lead small molecule compounds with drug-like properties that activate innate immune...
SBIR
Development of Kv1.3 channel blocker ShK-18...
Multiple sclerosis (MS) affects approximately 400,000 Americans and constitutes a progressive, disabling disease for which current t...
STTR
Therapeutic Potential of the Potassium Chan...
DESCRIPTION provided by applicant Systemic lupus erythematosus SLE is a chronic multisystem autoimmune disease with poorly unde...
SBIR
Development of novel isoflavone drugs as br...
Kineta has discovered a novel class of broad-spectrum small molecule antivirals that function through a host-directed mechanism. The...

Known Locations Served1

  • United States 1 location
My Notes
Contact
My Notes